In summary, we believe that this work expanded our knowledge of the crosstalk between tumor cells and immune cells, suggesting a potentially novel Egfl6-dependent signaling axis that drives recruitment and differentiation of immunosuppressive myeloid cells in the tumor, resulting in resistance to a-PD-L1 immunotherapy. This evidence concerns the gene EGFL6 and neoplasm.